Harold H. Shlevin net worth and biography

Harold Shlevin Biography and Net Worth

Director of Galectin Therapeutics

Dr. Shlevin is the retired former chief executive officer (CEO) and president of Galectin Therapeutics, now working with the Company on a consulting basis to help guide the Company’s ongoing Phase 2b/3 NASH-RX clinical trial. He is a bioscience industry executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics, and vaccines. Before joining Galectin Therapeutics as chief operating officer (COO) in 2012 and assuming the role of CEO and president in 2018, Dr. Shlevin led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as principal and manager of bioscience commercialization efforts, where he served as a catalyst for new bioscience startup companies. His leadership roles have included president and chief executive officer of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US; co-founder of CIBA Vision Ophthalmics, a specialty ophthalmic drug company, where he headed efforts leading to the approval of the first non-steroidal agent for treatment of ocular inflammation and several other drug products; founder, president and chief executive officer of Tikvah Therapeutics, a company focused on clinical development of therapeutics for treatment of neurological diseases; and vice president and head of operations and commercial development for Altea Therapeutics Corporation, a clinical-stage drug delivery company with platform technology applicable to the transdermal delivery of biologics. Dr. Shlevin earned his B.A. from Boston University and M.S. and Ph.D. in physiology from the University of Rochester Medical School. He completed post-doctoral training in pharmacology at Mayo Clinic where he subsequently served as assistant professor of pharmacology and physiology. He is a member of scientific and business societies including the Institute of Electrical and Electronics Engineers, Licensing Executives Society, American Physiological Society, American Society of Pharmacology and Experimental Therapeutics, and is an inventor on several issued and pending patents.

What is Harold H. Shlevin's net worth?: The estimated net worth of Harold H. Shlevin is at least $28.28 thousand as of June 29th, 2026. Dr. Shlevin owns 6,500 shares of Galectin Therapeutics stock worth more than $28,275 as of July 1st. This net worth estimate does not reflect any other investments that Dr. Shlevin may own. Learn More about Harold H. Shlevin's net worth.
How do I contact Harold H. Shlevin?: The corporate mailing address for Dr. Shlevin and other Galectin Therapeutics executives is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. Galectin Therapeutics can also be reached via phone at (678) 620-3186 and via email at [email protected]. Learn More on Harold H. Shlevin's contact information.
Has Harold H. Shlevin been buying or selling shares of Galectin Therapeutics?: Harold H. Shlevin has not been actively trading shares of Galectin Therapeutics within the last three months. Most recently, Harold H. Shlevin sold 22,268 shares of the business's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $5.04, for a transaction totalling $112,230.72. Following the completion of the sale, the director now directly owns 6,500 shares of the company's stock, valued at $32,760. Learn More on Harold H. Shlevin's trading history.
Who are Galectin Therapeutics' active insiders?: Galectin Therapeutics' insider roster includes Kevin Freeman (Director), Elissa Schwartz (Director), Harold Shlevin (Director), and Richard Zordani, Jr. (Director). Learn More on Galectin Therapeutics' active insiders.
Are insiders buying or selling shares of Galectin Therapeutics?: During the last twelve months, Galectin Therapeutics insiders bought shares 3 times. They purchased a total of 2,000 shares worth more than $6,341.00. During the last twelve months, insiders at the sold shares 32 times. They sold a total of 944,585 shares worth more than $5,050,478.51. The most recent insider tranaction occured on June, 29th when Director Harold H Shlevin sold 22,268 shares worth more than $112,230.72. Insiders at Galectin Therapeutics own 52.6% of the company. Learn More about insider trades at Galectin Therapeutics.
Information on this page was last updated on 6/29/2026.

Harold H. Shlevin Insider Trading History at Galectin Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/29/2026	Sell	22,268	$5.04	$112,230.72	6,500
6/26/2026	Sell	7,732	$5.00	$38,660.00	6,500
12/17/2025	Sell	24,499	$7.04	$172,472.96	6,500
12/9/2025	Sell	16,790	$6.27	$105,273.30	11,206
12/8/2025	Sell	159,000	$5.98	$950,820.00	11,206
12/30/2024	Buy	6,500	$1.16	$7,540.00	15,206
6/13/2018	Sell	43,698	$7.41	$323,802.18
6/11/2018	Sell	115,054	$5.84	$671,915.36	103,914
6/7/2018	Sell	109,969	$5.20	$571,838.80	58,094
6/5/2018	Sell	20,831	$5.15	$107,279.65	59,414
6/1/2018	Sell	119,200	$5.06	$603,152.00	103,914

Harold H. Shlevin Buying and Selling Activity at Galectin Therapeutics

Galectin Therapeutics Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $4.44

$4.28

$4.64

50 Day Range

MA: $2.65

$2.08

$4.97

2 Week Range

Now: $4.44

$2.03

$7.13

Volume

285,628 shs

Average Volume

459,155 shs

Market Capitalization

$292.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47